Research suggests that certain factors, including CCL3 and EGFR ligand Angiogenin, may predict response to specific inhibitions in pancreatic cancer. The role of tumor-associated macrophages and various chemical axes, such as CCR-CCL, are being explored in relation to pancreatic ductal adenocarcinoma. The studies indicate potential therapeutic strategies targeting the tumor immune microenvironment, although the specifics of these approaches are still being investigated.